Discovery of novel secretory antibody biosynthesis enables the first whole-human infant formula with antimicrobial antibodies that may protect newborns from gastrointestinal pathogens

Today, 108Labs announces the discovery of novel secretory antibody biosynthesis in the development of Colostrupedics™ whole-human infant formula, the first animal-free infant formula exclusively comprising cell-cultured human milk molecules derived from human mammary cell agriculture and formulated with broadly-neutralizing human secretory antibodies. Since 2013, 108Labs has pioneered mammary cell agriculture to free mothers as the exclusive producers of human milk molecules by developing the first infant formula biosimilar to mother’s milk with secretory antibodies.

“Whole-human” infant formula is made exclusively with human molecules produced with human cells. Formulated with patent-pending human cell-cultured ingredients comprising complex sugars, probiotic HMO, bioactive human proteins, and calorically dense human lipids naturally evolved in mothers, 108Labs’ Colostrupedics™ whole-human infant formula is poised to disrupt the infant nutrition market with a new whole-human ideal.

Whole-human infant formula contains a healthier amino acid pattern, fully human protein sequences, and human oligosaccharides missing from bovine formula. Infants, and their parents, stand to benefit from 108Labs’ animal-free formula that offers balanced nutrition naturally evolved for newborns alongside antimicrobial antibodies naturally evolved against mucosal pathogens.

“After a long journey, it is an exciting day to emerge with such an innovative product vision and major scientific milestones behind us. 108Labs has long dreamed of a day when mothers do not have to compromise on nutritional or antimicrobial benefits when deciding how to feed their newborns. Launching Colostrupedics™ whole-human infant formula with the world’s first human secretory antibody ingredient is a major step in our mission to replace bovine with healthier whole-human milk worldwide by 2040,” said Shayne Giuliano, co-founder and CEO of 108Labs.

108Labs is running pre-clinical safety and efficacy studies in preparation for infant nutritional trials with 108Labs’ Colostrupedics™ whole-human infant formula. For more information, please visit: https://colostrupedics.com

About 108Labs
108Labs is a biotechnology company founded in Research Triangle Park in 2013, with the objective to invent and develop novel cellular agriculture projects. With patent-pending technology development in the fields of mammary cell agriculture and secretory antibodies, 108Labs has led the development of cell cultured human milk, invented the personalized nutraceutical science behind Biomilq, and pioneered novel biosynthesis of human milk molecules and secretory antibodies in the development of Colostrupedics™ whole-human infant formula. 108Labs’ mission is to feed, build, and heal the world with Cellufacturing®.

108Labs, LLC, All Rights Reserved ©2021